Search

Displaying results 2051 - 2060 of 10000 in total
  1. Drug

    Oteracil

    go.drugbank.com/drugs/DB03209
    ApprovedInvestigational

    The main active ingredient in Teysuno is [DB09256], a pro-drug of [DB00544] (5-FU), which is a cytotoxic anti-metabolite drug that acts on rapidly dividing cancer cells. … Approved by the European Medicines Agency (EMA) in March 2011, Oteracil is available in combination with [DB09257] and [DB09256] within the commercially available product "Teysuno".

  2. Drug

    Nitisinone

    go.drugbank.com/drugs/DB00348
    Approved

    It is used in the treatment of hereditary tyrosinemia type 1 and Alkaptonuria. It is sold under the brand names Orfadin and Harliku. [L53253, L53258]

  3. Drug

    Bordetella pertussis pertactin antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB10992
    ApprovedInvestigational

    Mixtures: Repevax Injektionssuspension in einer Fertigspritze
  4. Drug

    Nipocalimab

    go.drugbank.com/drugs/DB16257
    ApprovedInvestigational

    [L64042] Nipocalimab-aahu was first approved by the FDA in April 2025 for generalized myasthenia gravis. … [L64042] This reduction in autoantibodies underlies its therapeutic effect across autoantibody-driven conditions.[L64042] It is administered by intravenous infusion.

  5. Drug

    Rolapitant

    go.drugbank.com/drugs/DB09291
    ApprovedInvestigational

    By blocking Substance P from interacting with NK-1 receptors in the gut and the central nervous system, rolapitant prevents late-phase CINV. … Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults.

  6. Drug

    Dicoumarol

    go.drugbank.com/drugs/DB00266
    Approved

    In addition to its clinical use, it is also used in biochemical experiments as an inhibitor of reductases. … Dicoumarol is an oral anticoagulant agent that works by interfering with the metabolism of vitamin K.

  7. Drug

    Bendazac

    go.drugbank.com/drugs/DB13501
    ApprovedWithdrawn

    Bendazac is an oxyacetic acid [A39863, A39869]. … the denaturation of proteins - an effect that has primarily proven useful in managing and delaying the progression of ocular cataracts [A39863.

  8. Drug

    Erdafitinib

    go.drugbank.com/drugs/DB12147
    ApprovedInvestigational

    [L5956, L5959] Considering urothelial cancer is statistically the fourth most common kind of cancer in the world, the introduction of erdafitinib offers a much-needed new option in the ever-expanding therapeutic … In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for

  9. Drug

    Tividenofusp alfa

    go.drugbank.com/drugs/DB17628
    ApprovedInvestigational

    Developed by Denali Therapeutics, tividenofusp alfa received FDA approval on March 25, 2026, under the accelerated approval pathway [L56097, L56099]. … Tividenofusp alfa is a first-in-class, brain-penetrant enzyme replacement therapy (ERT) indicated for the treatment of Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome [L56097, L56099

    Synonyms: - L-iduronate sulfate sulfatase, EC:3.1.6.13) pro-protein (1-525), fused via the peptide linker 526 GGGGS 530 to a human immunoglobulin G1 C-terminal Fc fragment (531-757) variant (L 544>A, L 545>A, T
  10. Drug

    Flurandrenolide

    go.drugbank.com/drugs/DB00846
    Approved

    (From Martindale, The Extra Pharmacopoeia, 30th ed, p733) … A corticosteroid used topically in the treatment of various skin disorders. It is usually employed as a cream or an ointment, and is also used as a polyethylene tape with an adhesive.